Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $112.9 million.

  • Kymera Therapeutics' Cash & Equivalents rose 2.02% to $112.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.9 million, marking a year-over-year increase of 2.02%. This contributed to the annual value of $120.3 million for FY2024, which is 9.36% up from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Cash & Equivalents is $112.9 million, which was down 66.37% from $335.8 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Cash & Equivalents peaked at $335.8 million during Q1 2025, and registered a low of $33.7 million during Q1 2022.
  • Over the past 3 years, Kymera Therapeutics' median Cash & Equivalents value was $110.0 million (recorded in 2023), while the average stood at $133.7 million.
  • In the last 5 years, Kymera Therapeutics' Cash & Equivalents crashed by 56.21% in 2021 and then skyrocketed by 396.68% in 2025.
  • Over the past 5 years, Kymera Therapeutics' Cash & Equivalents (Quarterly) stood at $48.0 million in 2021, then spiked by 42.56% to $68.4 million in 2022, then surged by 60.78% to $110.0 million in 2023, then rose by 9.36% to $120.3 million in 2024, then rose by 2.02% to $112.9 million in 2025.
  • Its last three reported values are $112.9 million in Q3 2025, $335.8 million for Q2 2025, and $335.8 million during Q1 2025.